Table 3.
Serum levels of TARC, SCF and CEA according to the GC carcinogenic sequences (upper) and between cancer and non-cancer groups (lower) in the independent validation dataset
| Group (N) | Normal (90) | High-risk (30) | EGC (50) | AGC (50) | P-value‡ |
|---|---|---|---|---|---|
| Serum TARC (ng/mL) | 67.5 ± 36.2† | 66.2 ± 47.7 | 109.1 ± 67.7 | 167.2 ± 111.1 | <0.001 |
| Serum SCF (ng/mL) | 6.3 ± 6.3 | 10.4 ± 7.8 | 17.3 ± 15.1 | 22.6 ± 20.4 | <0.001 |
| Serum CEA (ng/mL) | 1.8 ± 1.4 | 2.0 ± 0.8 | 1.7 ± 1.1 | 10.7 ± 19.8 | <0.001 |
| Group (N) | Non-cancer groups (120) | Cancer groups (100) | P-value§ |
|---|---|---|---|
| Serum TARC (ng/mL) | 62.3 ± 33.5† | 145.6 ± 95.4 | <0.001 |
| Serum SCF (ng/mL) | 7.0 ± 6.6 | 20.5 ± 18.5 | <0.001 |
| Serum CEA (ng/mL) | 1.9 ± 1.3 | 6.5 ± 15.1 | 0.05 |
All tested values are expressed as the mean ± standard deviation.
One-way analysis of variance test with the multiple comparisons using the post-hoc Bonferroni method is applied to compare the means among disease groups.
Independent sample t-test is applied to compare the means between cancer and non-cancer groups. P < 0.05 (two-tailed) was considered statistically significant. AGC, advanced gastric cancer; CEA, carcinoembryonic antigen; EGC, early gastric cancer; GC, gastric cancer; MCP-1, monocyte chemotactic protein-1; MDC, macrophage-derived chemokine; SCF, stem cell factor; TARC, thymus activation-regulated chemokine.